Exploring the Diagnosis and Profile of Cannabis Allergy.


Journal

The journal of allergy and clinical immunology. In practice
ISSN: 2213-2201
Titre abrégé: J Allergy Clin Immunol Pract
Pays: United States
ID NLM: 101597220

Informations de publication

Date de publication:
03 2019
Historique:
received: 17 07 2018
revised: 17 08 2018
accepted: 15 09 2018
pubmed: 3 10 2018
medline: 2 10 2020
entrez: 2 10 2018
Statut: ppublish

Résumé

Cannabis allergy (CA) has mainly been attributed to Can s 3, the nonspecific lipid transfer protein (nsLTP) of Cannabis sativa. Nevertheless, standardized diagnostic tests are lacking and research on CA is scarce. To explore the performance of 5 cannabis diagnostic tests and the phenotypic profile of CA. A total of 120 patients with CA were included and stratified according to the nature of their cannabis-related symptoms; 62 healthy and 189 atopic controls were included. Specific IgE (sIgE) hemp, sIgE and basophil activation test (BAT) with a recombinant Can s 3 protein from Cannabis sativa (rCan s 3), BAT with a crude cannabis extract, and a skin prick test (SPT) with an nCan s 3-rich cannabis extract were performed. Clinical information was based on patient history and a standardized questionnaire. First, up to 72% of CA reporting likely-anaphylaxis (CA-A) are Can s 3 sensitized. Actually, the Can s 3-based diagnostic tests show the best combination of positive and negative predictive values, 80% and 60%, respectively. sIgE hemp displays 82% sensitivity but only 32% specificity. Secondly, Can s 3+CA reported significantly more cofactor-mediated reactions and displayed significantly more sensitizations to other nsLTPs than Can s 3-CA. Finally, the highest prevalence of systemic reactions to plant-derived foods was seen in CA-A, namely 72%. The most effective and practical tests to confirm CA are the SPT with an nCan s 3-rich extract and the sIgE rCan s 3. Can s 3 sensitization entails a risk of systemic reactions to plant-derived foods and cofactor-mediated reactions. However, as Can s 3 sensitization is not absolute, other cannabis allergens probably play a role.

Sections du résumé

BACKGROUND
Cannabis allergy (CA) has mainly been attributed to Can s 3, the nonspecific lipid transfer protein (nsLTP) of Cannabis sativa. Nevertheless, standardized diagnostic tests are lacking and research on CA is scarce.
OBJECTIVE
To explore the performance of 5 cannabis diagnostic tests and the phenotypic profile of CA.
METHODS
A total of 120 patients with CA were included and stratified according to the nature of their cannabis-related symptoms; 62 healthy and 189 atopic controls were included. Specific IgE (sIgE) hemp, sIgE and basophil activation test (BAT) with a recombinant Can s 3 protein from Cannabis sativa (rCan s 3), BAT with a crude cannabis extract, and a skin prick test (SPT) with an nCan s 3-rich cannabis extract were performed. Clinical information was based on patient history and a standardized questionnaire.
RESULTS
First, up to 72% of CA reporting likely-anaphylaxis (CA-A) are Can s 3 sensitized. Actually, the Can s 3-based diagnostic tests show the best combination of positive and negative predictive values, 80% and 60%, respectively. sIgE hemp displays 82% sensitivity but only 32% specificity. Secondly, Can s 3+CA reported significantly more cofactor-mediated reactions and displayed significantly more sensitizations to other nsLTPs than Can s 3-CA. Finally, the highest prevalence of systemic reactions to plant-derived foods was seen in CA-A, namely 72%.
CONCLUSIONS
The most effective and practical tests to confirm CA are the SPT with an nCan s 3-rich extract and the sIgE rCan s 3. Can s 3 sensitization entails a risk of systemic reactions to plant-derived foods and cofactor-mediated reactions. However, as Can s 3 sensitization is not absolute, other cannabis allergens probably play a role.

Identifiants

pubmed: 30273677
pii: S2213-2198(18)30594-4
doi: 10.1016/j.jaip.2018.09.017
pii:
doi:

Substances chimiques

Allergens 0
Antigens, Plant 0
Can s 3 allergen, Cannabis sativa 0
Carrier Proteins 0
Plant Proteins 0
Immunoglobulin E 37341-29-0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

983-989.e5

Informations de copyright

Copyright © 2018. Published by Elsevier Inc.

Auteurs

Ine Ilona Decuyper (II)

Department of Immunology-Allergology-Rheumatology, University Hospital of Antwerp, University of Antwerp, Antwerp, Belgium; Department of Pediatrics, University Hospital of Antwerp, University of Antwerp, Antwerp, Belgium.

Athina Ludovica Van Gasse (AL)

Department of Immunology-Allergology-Rheumatology, University Hospital of Antwerp, University of Antwerp, Antwerp, Belgium.

Margaretha A Faber (MA)

Department of Immunology-Allergology-Rheumatology, University Hospital of Antwerp, University of Antwerp, Antwerp, Belgium.

Jessy Elst (J)

Department of Immunology-Allergology-Rheumatology, University Hospital of Antwerp, University of Antwerp, Antwerp, Belgium.

Christel Mertens (C)

Department of Immunology-Allergology-Rheumatology, University Hospital of Antwerp, University of Antwerp, Antwerp, Belgium.

Hans-Peter Rihs (HP)

IPA-Institute for Prevention and Occupational Medicine, German Social Accident Insurance, Ruhr-University Bochum, Bochum, Germany.

Margo M Hagendorens (MM)

Department of Immunology-Allergology-Rheumatology, University Hospital of Antwerp, University of Antwerp, Antwerp, Belgium; Department of Pediatrics, University Hospital of Antwerp, University of Antwerp, Antwerp, Belgium.

Vito Sabato (V)

Department of Immunology-Allergology-Rheumatology, University Hospital of Antwerp, University of Antwerp, Antwerp, Belgium.

Hilde Lapeere (H)

Ghent University Hospital, University of Ghent, Ghent, Belgium.

Chris H Bridts (CH)

Department of Immunology-Allergology-Rheumatology, University Hospital of Antwerp, University of Antwerp, Antwerp, Belgium.

Luc S De Clerck (LS)

Department of Immunology-Allergology-Rheumatology, University Hospital of Antwerp, University of Antwerp, Antwerp, Belgium.

Didier Gaston Ebo (DG)

Department of Immunology-Allergology-Rheumatology, University Hospital of Antwerp, University of Antwerp, Antwerp, Belgium. Electronic address: immuno@uantwerpen.be.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH